Drugplain

Travoprost .04 mg/mL

Travoprost (Isomer Free) · SOLUTION/ DROPS · Somerset Therapeutics, LLC

4 Recalls on Record
Plain English

Travoprost is a solution/ drops containing travoprost (isomer free) at .04 mg/mL, taken ophthalmic. Manufactured by Somerset Therapeutics, LLC.

Key Facts

Brand Name
Travoprost
Generic Name
Travoprost (Isomer Free)
NDC Code (Product)
70069-587
Manufacturer
Somerset Therapeutics, LLC
Strength
.04 mg/mL
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Marketing Status
Application #
ANDA217228
Drug Class
Prostaglandin Analog [EPC]
Marketing Start
10/10/2024

Recall History

4 Recalls on Record
Class II10/05/2016

Par Pharmaceutical, Inc.

Lack of Assurance of Sterility; damage to the internal portion of the dropper tip portion of the container

TerminatedVoluntary: Firm initiated
Class II04/01/2022

Mylan Pharmaceuticals Inc

Subpotent Drug and Failed Impurities/Degradation Specifications: low out-of-specification results obtained for assay and high out-of-specification results for related substance impurities/degradation during routine stability testing.

TerminatedVoluntary: Firm initiated
Class II05/25/2023

Golden State Medical Supply Inc.

Lack of Assurance of Sterility: Tamper Evidence Seal is missing on secondary container.

TerminatedVoluntary: Firm initiated
Class II03/15/2021

Cardinal Health Inc.

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

treatment failure890 reports
drug ineffective181 reports
eye irritation118 reports
fatigue110 reports
off label use106 reports
dyspnoea104 reports
dizziness98 reports
product dose omission issue98 reports
cough93 reports
diarrhoea92 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE Travoprost ophthalmic solution (ionic buffered solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Travoprost ophthalmic solution (ionic buffered solution) is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 )

Dosage & Administration

2 DOSAGE AND ADMINISTRATION The recommended dosage is one drop in the affected eye(s) once daily in the evening. Travoprost ophthalmic solution (ionic buffered solution) should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the IOP lowering effect. Reduction of the IOP starts approximately 2 hours after the first administration with maximum effect reached after 12 hours. Travoprost ophthalmic solution (ionic buffered solution) may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart. One drop in the affected eye(s) once daily in the evening. ( 2 )

Contraindications

4 CONTRAINDICATIONS None. None ( 4 )

Adverse Reactions

6 ADVERSE REACTIONS Most common adverse reaction (30% to 50%) is conjunctival hyperemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reaction observed in controlled clinical trials with travoprost ophthalmic solution 0.004% was ocular hyperemia, which was reported in 30% to 50% of patients. Up to 3% of patients discontinued therapy due to conjunctival hyperemia. Ocular adverse reactions reported at an incidence of 5% to 10% in these clinical trials included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus. Ocular adverse reactions reported at an incidence of 1% to 4% in clinical trials with travoprost ophthalmic solution 0.004% included abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, dry ey

Frequently Asked Questions

What is Travoprost used for?

Travoprost contains Travoprost (Isomer Free). It is a solution/ drops taken ophthalmic. Consult your doctor for specific uses.

Is Travoprost a controlled substance?

Travoprost is not classified as a controlled substance by the DEA.

What is the generic name for Travoprost?

The generic name for Travoprost is Travoprost (Isomer Free). There are no other listed brand versions of Travoprost (Isomer Free).

What is the NDC code for Travoprost .04 mg/mL?

The NDC (National Drug Code) for Travoprost .04 mg/mL is 70069-587, listed by Somerset Therapeutics, LLC.

Product NDC

70069-587

Package NDC

70069-587-01

Other Travoprost Dosages

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)